Assuming optimization of patient outcomes, rather than cost, is the primary driver governing use of PCSK9 inhibitors, which patients in a medical cardiology practice would you single out for this therapy, and to achieve what LDL-C target levels?

Assuming optimization of patient outcomes, rather than cost, is the primary driver governing use of PCSK9 inhibitors, which patients in a medical cardiology practice would you single out for this therapy, and to achieve what LDL-C target levels?

CLICK HERE FOR CME CREDIT

Assuming optimization of patient outcomes, rather than cost, is the primary driver governing use of PCSK9 inhibitors, which patients in a medical cardiology practice would you single out for this therapy, and to achieve what LDL-C target levels?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Robert Rosenson, MD

Robert Rosenson, MD

Professor of Medicine (Cardiology) Mount Sinai Icahn School of Medicine Director, Cardiometabolics Unit Mount Sinai Heart Institute New York, NY